CVS Group plc (LSE:CVSG) shares fell 0.77% to 1,294.0p in the latest session, placing the veterinary services group among the notable decliners on the London market. The move follows its final results for the year ended 30 June 2026, which showed higher revenue and earnings per share, alongside increased net borrowings and the conclusion of a regulatory review of the UK veterinary market.
The results highlight a group that is growing through acquisitions in Australia and the UK while adapting to a new regulatory framework.
Key Highlights
CVS Group reported FY2026 revenue of £712.8 million, up 5.9% from £673.2 million. Like-for-like sales growth was 2.1%, compared with 0.2% the previous year.
Adjusted EBITDA increased 5.1% to £141.5 million, and the adjusted EBITDA margin was 19.9%, within the stated 19% to 23% range. Adjusted earnings per share rose 6.9% to 85.6p.
Profit before tax was £32.0 million, compared with £32.6 million, while adjusted profit before tax was £84.9 million.
Net bank borrowings were £199.6 million, up from £131.4 million, with leverage of 1.63x, below the group's 2.0x policy ceiling. The final dividend is 9.0p, up from 8.5p.
About CVS Group plc
CVS Group plc (LSE:CVSG) operates more than 480 veterinary practices across the United Kingdom and Australia. Its activities include companion animal practices, referral services, laboratories and an online retail business, Animed Direct.
The Veterinary Practices division generated revenue of £648.2 million, representing 88.3% of group revenue. Laboratories generated revenue of £35.0 million, up 11.5%, while Animed Direct recorded revenue of £51.0 million, up 11.1%.
Nearly all UK companion animal first-opinion and referral practices are now jointly branded as "CVS Vets", and the group estimates its UK market share at around 8% to 9%. The company moved from AIM to the Main Market in January 2026 and joined the FTSE 250 in March 2026.
Why Is LSE:CVSG Down Today?
The 0.77% decline to 1,294.0p reflects a modest adjustment after a period of results and regulatory news. The company delivered growth in revenue and adjusted earnings, but investors are also considering the rise in debt, the cost of remedies and a leadership transition.
Net bank borrowings increased by around £68 million over the year, reflecting acquisitions and share buybacks. Leverage rose to 1.63x from 1.18x, although it remains within the group's policy.
The Competition and Markets Authority's veterinary market investigation has concluded, with final remedies published on 22 September 2026, mostly focused on transparency. The group said most remedies are implemented or in progress, with implementation costs of £5.1 million treated as exceptional items.
In addition, CEO Richard Fairman intends to retire, and the board is searching for a successor.
Key Reasons Behind the Downtick
The first factor is regulatory change. Even though the remedies focus mainly on transparency, they may influence pricing practices and customer behaviour across the sector.
The second factor is higher leverage. Net borrowings rose to £199.6 million, and further acquisitions of around £50 million a year are planned.
Third, profit before tax was slightly lower at £32.0 million despite revenue growth, reflecting items such as exceptional costs and higher finance charges.
Another consideration is veterinary practice like-for-like growth, which was 1.0%, lower than the group figure of 2.1%.
Finally, leadership succession introduces uncertainty until a new chief executive is appointed.
Key Growth Catalysts
The most important catalyst is Australian expansion. Australian revenue rose to £79.1 million from £52.1 million, now about 11% of group revenue, with 35 practices across 57 sites. Six practices comprising 14 sites were acquired during the year, and two further Australian acquisitions have been announced since year-end.
UK acquisitions are also continuing. Contracts were exchanged on a two-site UK practice for £15.0 million initial consideration, with completion pending.
A third catalyst is ancillary businesses. Laboratories and Animed Direct both grew at double-digit rates.
The group has a medium-term target of 4% to 8% like-for-like organic growth, and the new financial year started with positive like-for-like sales growth.
Finally, capital returns continue. A £20 million buyback was completed in January 2026, and a further £50 million programme began in May 2026, with £11.7 million completed by year-end.
Risks
The most significant risk for LSE:CVSG is the effect of regulation on pricing and revenue per customer. Greater transparency can increase price comparison and affect margins.
Cost inflation is another risk. Veterinary salaries, medicines and equipment costs can rise faster than prices.
Staff availability is also relevant. The veterinary profession relies on skilled clinicians and nurses, and recruitment or retention pressures can affect capacity.
Acquisition risk matters too. Integrating practices requires management time and can affect near-term returns, especially in a new market such as Australia.
Finally, higher borrowings mean that interest costs and covenant compliance remain relevant, although leverage of 1.63x is below the 3.25x covenant.
Valuation
The valuation of LSE:CVSG is likely to be viewed through earnings growth, acquisition returns and the regulatory outlook.
At 1,294.0p, investors are weighing adjusted earnings per share of 85.6p, a medium-term growth target of 4% to 8% and an expanding Australian business against higher debt and a changing regulatory environment.
Consensus expectations cited in the results for FY27 were average adjusted EBITDA of £150.4 million and adjusted earnings per share of 94.9p, and the company said FY27 performance is expected to be in line with market expectations.
The central valuation question is whether acquisition-led growth and pricing discipline can offset regulatory and cost pressures.
What Investors Should Watch Next
The next scheduled events include the ex-dividend date on 7 November 2026, the AGM on 25 November 2026 and payment of the final dividend on 4 December 2026.
Investors should follow progress on CEO succession, the delivery of CMA remedies and any change in customer behaviour linked to price transparency.
Other points to monitor include the pace of Australian and UK acquisitions, like-for-like growth against the 4% to 8% target, net debt and the completion of the £50 million buyback.
For LSE:CVSG, the central question over the coming quarters is whether the group can maintain growth while adapting to a new regulatory framework.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...